N-(3,4-dichlorophenyl)-4-(imidazo[1,2-b]pyridazin-6-yl)piperazine-1-carboxamide

ID: ALA5284926

Max Phase: Preclinical

Molecular Formula: C17H16Cl2N6O

Molecular Weight: 391.26

Names and Identifiers

Canonical SMILES:  O=C(Nc1ccc(Cl)c(Cl)c1)N1CCN(c2ccc3nccn3n2)CC1

Standard InChI:  InChI=1S/C17H16Cl2N6O/c18-13-2-1-12(11-14(13)19)21-17(26)24-9-7-23(8-10-24)16-4-3-15-20-5-6-25(15)22-16/h1-6,11H,7-10H2,(H,21,26)

Standard InChI Key:  CUGOWUCSKIIZFS-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 29  0  0  0  0  0  0  0  0999 V2000
   -0.2750   -0.4125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2750    0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4400    0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1550    0.4125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1550   -0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4400   -0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8700    0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8700    1.6500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5850    2.0625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3001    1.6500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3001    0.8250    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5850    0.4125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.0976    0.5775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5650    1.2374    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0976    1.8975    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9900   -0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9900   -1.6500    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7050   -0.4125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4201   -0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1351   -0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8501   -0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8501   -1.6500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1351   -2.0625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4201   -1.6500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5650   -2.0625    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -4.5650   -0.4125    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  1  6  1  0
  5  6  1  0
  4  7  1  0
  8  7  1  0
  9  8  2  0
 10  9  1  0
 10 11  1  0
 12 11  1  0
  7 12  2  0
 13 11  1  0
 14 13  2  0
 15 10  2  0
 15 14  1  0
  1 16  1  0
 16 17  2  0
 16 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 19 24  2  0
 23 24  1  0
 22 25  1  0
 21 26  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5284926

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 391.26

Molecular Weight (Monoisotopic): 390.0763

AlogP: 3.39

#Rotatable Bonds: 2

Polar Surface Area: 65.77

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 13.12

CX Basic pKa: 4.24

CX LogP: 3.55

CX LogD: 3.55

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.73

Np Likeness Score: -2.69

References

1. Oboh E, Teixeira JE, Schubert TJ, Maribona AS, Denman BN, Patel R, Huston CD, Meyers MJ..  (2023)  Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633.,  86  [PMID:37148788] [10.1016/j.bmc.2023.117295]

Source

Source(1):

• Scientific Literature